Literature DB >> 10217600

Induction of mucosal immunity with a replication-defective adenoviral recombinant.

Z Xiang1, H C Ertl.   

Abstract

A replication-defective adenoviral recombinant expressing the rabies virus glycoprotein was tested for induction of transgene specific central and mucosal antibodies upon systemic inoculation or upon application to the mucosa of the airways, the rectum or the female genital tract. Mice developed serum and mucosal antibody titers to rabies virus upon subcutaneous or intranasal immunization with the latter route favoring induction of genital and intestinal secretion of antibodies of the IgA isotype. Immunization through the mucosa of the genital tract or the rectum was inefficient. Mucosal and systemic antibody titers could be increased by intranasal priming followed by a booster immunization with the same construct.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10217600     DOI: 10.1016/s0264-410x(98)00449-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Enhancement of recombinant adenovirus vaccine-induced primary but not secondary systemic and mucosal immune responses by all-trans retinoic acid.

Authors:  Steven Tuyishime; Larissa H Haut; Caihong Zhu; Hildegund C J Ertl
Journal:  Vaccine       Date:  2014-04-26       Impact factor: 3.641

2.  Enhancement of nasal HIV vaccination with adenoviral vector-based nanocomplexes using mucoadhesive and DC-targeting adjuvants.

Authors:  Yuhong Jiang; Man Li; Zhirong Zhang; Tao Gong; Xun Sun
Journal:  Pharm Res       Date:  2014-05-03       Impact factor: 4.200

3.  Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier.

Authors:  Z Q Xiang; G P Gao; A Reyes-Sandoval; Y Li; J M Wilson; H C J Ertl
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

4.  Vaccination with recombinant adenovirus expressing multi-stage antigens of Toxoplasma gondii by the mucosal route induces higher systemic cellular and local mucosal immune responses than with other vaccination routes.

Authors:  Ting Wang; Huiquan Yin; Yan Li; Lingxiao Zhao; Xiahui Sun; Hua Cong
Journal:  Parasite       Date:  2017-04-03       Impact factor: 3.000

5.  Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats.

Authors:  Ran-Yi Liu; Li-Zhi Wu; Bi-Jun Huang; Jia-Ling Huang; Yan-Ling Zhang; Miao-La Ke; Jun-Mei Wang; Wei-Ping Tan; Ru-Hua Zhang; Han-Kui Chen; Yi-Xin Zeng; Wenlin Huang
Journal:  Virus Res       Date:  2005-09       Impact factor: 3.303

6.  Synthetic immunotherapy induces HIV virus specific Th1 cytotoxic response and death of an HIV-1 infected human cell line through classic complement activation.

Authors:  Olga Pleguezuelos; Gregory A Stoloff; Wilson Caparrós-Wanderley
Journal:  Virol J       Date:  2013-04-04       Impact factor: 4.099

Review 7.  Adenoviruses as vaccine vectors.

Authors:  Nia Tatsis; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2004-10       Impact factor: 11.454

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.